Oncotarget

Research Papers: Gerotarget (Focus on Aging):

Quantifying signaling pathway activation to monitor the quality of induced pluripotent stem cells

Eugene Makarev _, Kristen Fortney, Maria Litovchenko, Karl H. Braunewell, Alex Zhavoronkov, Anthony Atala

PDF |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2015; 6:23204-23212. https://doi.org/10.18632/oncotarget.4673

Metrics: HTML 502 views  |   ?  


Abstract

Eugene Makarev1,2, Kristen Fortney1,3, Maria Litovchenko4, Karl H. Braunewell5, Alex Zhavoronkov2,6, Anthony Atala1,7

1Atlas Regeneration, Inc, Winston-Salem, NC, USA

2Insilico Medicine, Inc, ETC, Johns Hopkins University, Baltimore, MD, USA

3Department of Developmental Biology, Stanford University Medical Center, Stanford, CA, USA

4Department of Computational Genomics, Ludwig Maximilian University of Munich, Germany

5Department of Neurophysiology, Medical Faculty, Ruhr University Bochum, Germany

6The Biogerontology Research Foundation, London, UK

7Department of Urology, Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

Correspondence to:

Eugene Makarev, e-mail: gene.atlasregen@mail.com

Anthony Atala, e-mail: atlasregen@mail.com

Keywords: Gerotarget, bioinformatics, algorithm, embryonic stem cells, pathway activation, iPSC

Received: April 27, 2015     Accepted: August 10, 2015     Published: August 22, 2015

ABSTRACT

Many attempts have been made to evaluate the safety and potency of human induced pluripotent stem cells (iPSCs) for clinical applications using transcriptome data, but results so far have been ambiguous or even contradictory. Here, we characterized stem cells at the pathway level, rather than at the gene level as has been the focus of previous work. We meta-analyzed publically-available gene expression data sets and evaluated signaling and metabolic pathway activation profiles for 20 human embryonic stem cell (ESC) lines, 12 human iPSC lines, five embryonic body lines, and six fibroblast cell lines. We demonstrated the close resemblance of iPSCs with ESCs at the pathway level, and provided examples of how pathway activity can be applied to identify iPSC line abnormalities or to predict in vitro differentiation potential. Our results indicate that pathway activation profiling is a promising strategy for evaluating the safety and potency of iPSC lines in translational medicine applications.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4673